ZyVersa Therapeutics Inc
For the period ended Dec 31, 2023. Filed Mar 25, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 25, 2024
ZVSA$0.00-90.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 14. Principal Accounting Fees and Services
ITEM 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES
| 2022- | 2022- | |||||
| Type of Fees | 2023 | Successor | Predecessor | |||
|---|---|---|---|---|---|---|
| Audit Fees [1][2] | $848,160 | $228,000 | $810,353 | |||
| Audit-Related Fees [3] | - | - | - | |||
| Tax Fees [4] | - | - | 19,054 | |||
| Total | $848,160 | $228,000 | $829,587 | |||
| (1) | Audit fees are fees for professional services rendered in connection with the audit of our consolidated financial statements, statutory filings and registration statements, review of interim financial statements, the review of documents filed with the Securities and Exchange Commission, comfort letters, consents and certain accounting and consultations in connection with the audits. |
| (2) | Audit fees for the year ended December 31, 2023 include professional fees incurred by Ernst and Young of $663,160 and Marcum of $185,000. |
| (3) | Audit-related fees are fees for services related to accounting consultation and compliance with regulatory requirements and are not reported under “Audit Fees”. |
| (4) | Tax fees are for services related to tax compliance, tax planning and tax advice. These services included annual U.S. federal and state compliance and preparation of related tax returns and reports. |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.